NEW YORK – CStone Pharmaceuticals said on Thursday that its new drug application of avapritinib (Ayvakit) for PDGFRA exon 18-mutated metastatic or unresectable gastrointestinal stromal tumors was accepted by China's National Medical Products Administration.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.